{
    "name": "lutetium Lu 177-dota-tate",
    "comment": "Rx",
    "other_names": [
        "Lutathera"
    ],
    "classes": [
        "Radiopharmaceuticals"
    ],
    "source": "https://reference.medscape.com/drug/lutathera-lutetium-lu-177-dota-tate-1000113",
    "pregnancy": {
        "common": [
            "Based on its mechanism of action, can cause fetal harm and infertility",
            "No data are available regarding use in pregnant women; however, all oncology#radiopharmaceuticals have the potential to cause fetal harm",
            "Advise pregnant women of the risk to a fetus",
            "Verify pregnancy status of females of reproductive potential prior to initiating"
        ],
        "specific": [
            {
                "type": "Infertility",
                "description": [
                    "May cause infertility in males and females",
                    "The recommended cumulative dose of 29.6 GBq results in a radiation absorbed dose to the testis and ovaries within the range in which temporary or permanent infertility can be expected following external beam radiotherapy"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females: Advise females of reproductive potential to use effective contraception during treatment and for 7 months after the final dose",
                    "Males: Advise males with female partners of reproductive potential to use effective contraception during and for 4 months after the final dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of lutetium Lu 177 dotatate in human milk, or its effects on the breastfed infant or milk production",
            "No lactation studies in animals were conducted",
            "Because of the potential risk for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for 2.5 months after the final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Drug contributes to a patientâ€™s overall long-term cumulative radiation exposure; long-term cumulative radiation exposure is associated with an increased risk for cancer; radiation can be detected in the urine for up to 30 days; minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with institutional good radiation safety practices and patient management procedures",
                "Myelosuppression may occur; monitor blood cell counts; withhold dose, reduce dose, or permanently discontinue therapy based on severity of myelosuppression",
                "Secondary myelodysplastic syndrome and leukemia reported",
                "Renal failure development may occur up to 36 mo after treatment; administer the recommended amino acid solution before, during, and after lutetium Lu 177-dota-tate to decrease reabsorption through the proximal tubules and decrease the radiation dose to the kidneys; monitor serum creatinine and calculated creatinine clearance; withhold dose, reduce dose, or permanently discontinue therapy based on severity of renal toxicity; patients with baseline renal impairment may be at increased risk of toxicity due to increased radiation exposure (see Adult Dosing and Dosage Modifications)",
                "Rare reports of hepatotoxicity; monitor transaminases, bilirubin, serum albumin, and international normalized ratio (INR) during treatment; withhold dose, reduce dose, or permanently discontinue therapy based on severity of hepatotoxicity (see Dosage Modifications)",
                "Neuroendocrine hormonal crises, manifesting with flushing, diarrhea, bronchospasm, and hypotension, reported; typically occurs during or within 24 hr after initial dose; monitor patients for flushing, diarrhea, hypotension, bronchoconstriction, or other signs and symptoms of tumor-related hormonal release; administer IV somatostatin analogs, fluids, corticosteroids, and electrolytes as indicated",
                "Corticosteroids can induce down-regulation of subtype 2 somatostatin receptors (SST2); avoid repeated administration of high-doses of glucocorticosteroids during treatment",
                "Hepatic tumor hemorrhage, edema, or necrosis, reported with rare reports of intrahepatic congestion and cholestasis; patients with hepatic metastasis may be at increased risk of hepatotoxicity due to radiation exposure; monitor transaminases, bilirubin and serum albumin during treatment; withhold, reduce dose, or permanently discontinue therapy based on severity of hepatotoxicity",
                "Can cause fetal harm and infertility in males and females based on mechanism of action (see Pregnancy)"
            ],
            "specific": [
                {
                    "type": "Hypersensitivity reactions",
                    "description": [
                        "Hypersensitivity reactions, including angioedema, reported; monitor patients closely for signs and symptoms of hypersensitivity reactions, including anaphylaxis, during and following therapy administration for a minimum of 2 hr in a setting where cardiopulmonary resuscitation medication and equipment are available",
                        "Discontinue infusion upon first observation of any signs or symptoms consistent with a severe hypersensitivity reaction, and initiate appropriate therapy",
                        "Premedicate patients with history of Grade 1 or 2 hypersensitivity reactions to therapy before subsequent doses; permanently discontinue therapy in patients who experience Grade 3 or 4 hypersensitivity reactions"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Somatostatin and its analogs competitively bind to somatostatin receptors and may interfere with lutetium Lu 177-dota-tate efficacy (see Adult Dosing)"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lanreotide",
            "description": {
                "common": "lanreotide decreases effects of lutetium Lu 177-dota-tate by receptor binding competition. Modify Therapy/Monitor Closely. Somatostatin analogs competitively bind to the same somatostatin receptors as lutetium Lu 177-dota-tate and may affect its efficacy. Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hr prior to each lutetium Lu 177-dota-tate dose. Administer short- and long-acting octreotide during treatment as recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "octreotide",
            "description": {
                "common": "octreotide decreases effects of lutetium Lu 177-dota-tate by receptor binding competition. Modify Therapy/Monitor Closely. Somatostatin analogs competitively bind to the same somatostatin receptors as lutetium Lu 177-dota-tate and may affect its efficacy. Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hr prior to each lutetium Lu 177-dota-tate dose. Administer short- and long-acting octreotide during treatment as recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pasireotide",
            "description": {
                "common": "pasireotide decreases effects of lutetium Lu 177-dota-tate by receptor binding competition. Modify Therapy/Monitor Closely. Somatostatin analogs competitively bind to the same somatostatin receptors as lutetium Lu 177-dota-tate and may affect its efficacy. Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hr prior to each lutetium Lu 177-dota-tate dose. Administer short- and long-acting octreotide during treatment as recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and lutetium Lu 177-dota-tate both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Lymphopenia",
            "percent": "90"
        },
        {
            "name": "Creatinine increased",
            "percent": "85"
        },
        {
            "name": "Hyperglycemia",
            "percent": "82"
        },
        {
            "name": "Anemia",
            "percent": "81"
        },
        {
            "name": "Increased GGT",
            "percent": "66"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "65"
        },
        {
            "name": "Nausea",
            "percent": "65"
        },
        {
            "name": "Leukopenia",
            "percent": "55"
        },
        {
            "name": "Vomiting",
            "percent": "53"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "53"
        },
        {
            "name": "AST increased",
            "percent": "50"
        },
        {
            "name": "ALT increased",
            "percent": "43"
        },
        {
            "name": "Fatigue",
            "percent": "38"
        },
        {
            "name": "Hyperuricemia",
            "percent": "34"
        },
        {
            "name": "Hypocalcemia",
            "percent": "32"
        },
        {
            "name": "Blood bilirubin increased",
            "percent": "30"
        },
        {
            "name": "Hypokalemia",
            "percent": "26"
        },
        {
            "name": "Abdominal pain",
            "percent": "26"
        },
        {
            "name": "Diarrhea",
            "percent": "26"
        },
        {
            "name": "Neutropenia",
            "percent": "26"
        },
        {
            "name": "Decreased appetite",
            "percent": "21"
        },
        {
            "name": "Hyperkalemia",
            "percent": "19"
        },
        {
            "name": "Hypernatremia",
            "percent": "17"
        },
        {
            "name": "Headache",
            "percent": "17"
        },
        {
            "name": "Dizziness",
            "percent": "17"
        },
        {
            "name": "Peripheral edema",
            "percent": "16"
        },
        {
            "name": "Hypoglycemia",
            "percent": "15"
        },
        {
            "name": "Flushing",
            "percent": "14"
        },
        {
            "name": "Back pain",
            "percent": "13"
        },
        {
            "name": "Anxiety",
            "percent": "12"
        },
        {
            "name": "Renal failure",
            "percent": "12"
        },
        {
            "name": "Alopecia",
            "percent": "12"
        },
        {
            "name": "Hypertension",
            "percent": "12"
        },
        {
            "name": "Pain in extremity",
            "percent": "11"
        },
        {
            "name": "Cough",
            "percent": "11"
        },
        {
            "name": "Lymphopenia",
            "percent": "44"
        },
        {
            "name": "Increased GGT",
            "percent": "20"
        },
        {
            "name": "Constipation",
            "percent": "10"
        },
        {
            "name": "Pyrexia",
            "percent": "8"
        },
        {
            "name": "Dysgeusia",
            "percent": "8"
        },
        {
            "name": "Radiation",
            "percent": "8"
        },
        {
            "name": "related toxicity to urinary tract",
            "percent": "5"
        },
        {
            "name": "Atrial fibrillation",
            "percent": "5"
        },
        {
            "name": "Myalgia",
            "percent": "5"
        },
        {
            "name": "Neck pain",
            "percent": "7"
        },
        {
            "name": "Vomiting",
            "percent": "6"
        },
        {
            "name": "Hyperuricemia",
            "percent": "5"
        },
        {
            "name": "Nausea",
            "percent": "5"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "5"
        },
        {
            "name": "AST increased",
            "percent": "4"
        },
        {
            "name": "ALT increased",
            "percent": "4"
        },
        {
            "name": "Hyperglycemia",
            "percent": "4"
        },
        {
            "name": "Hypokalemia",
            "percent": "3"
        },
        {
            "name": "Renal failure",
            "percent": "3"
        },
        {
            "name": "Abdominal pain",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": "3"
        },
        {
            "name": "Neutropenia",
            "percent": "2"
        },
        {
            "name": "Back pain",
            "percent": "2"
        },
        {
            "name": "Hypertension",
            "percent": "2"
        },
        {
            "name": "Leukopenia",
            "percent": "2"
        },
        {
            "name": "Blood bilirubin increased",
            "percent": "1"
        },
        {
            "name": "Anxiety",
            "percent": "1"
        },
        {
            "name": "Atrial fibrillation",
            "percent": "1"
        },
        {
            "name": "Fatigue",
            "percent": "1"
        },
        {
            "name": "Cough",
            "percent": "1"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "1"
        },
        {
            "name": "Creatinine increased",
            "percent": null
        }
    ]
}